New directions in the treatment of normal tension glaucoma

Indian Journal of Ophthalmology

Volumn 62, Issue 5, 2014, Pages 529-537

  Song, Brian J ^a,b   Caprioli, Joseph ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Intraocular pressure; low tension glaucoma; neuroprotection; normal tension glaucoma; risk factors

Indexed keywords

DISEASE MANAGEMENT; HUMAN; LOW TENSION GLAUCOMA; PRACTICE GUIDELINE;

DISEASE MANAGEMENT; HUMANS; LOW TENSION GLAUCOMA; PRACTICE GUIDELINES AS TOPIC;

EID: 84901822042     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.133481     Document Type: Review

References (147)

1. Obstbaum SA, Cioffi GA, Krieglstein GK, Fennerty MB, Alm A, Araie M, et al. Gold standard medical therapy for glaucoma: Defining the criteria identifying measures for an evidence-based analysis. Clin Ther 2004;26:2102-20.
2. Von Graefe A. Amaurose mit sehnervenexcavation. Graefes Arch Clin Exp Ophthalmol 1857;3:484.
3. Schnabel WJ. Klinische daten zur entwicklungsgeschichte der glaucomatosen. Zeitschr Augenheilkd 1908;19:335.
4. Levine RZ. Low-tension glaucoma: A critical review and new material. Surv Ophthalmol 1980;24:621-63.
5. Sommer A, Tielsch JM, Katz J, Quigley HA, Gott sch JD, Javitt J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-5.
6. Tielsch JM, Katz J, Singh K, Quigley HA, Gott sch JD, Javitt J, et al. A population based evaluation of glaucoma screening: The Baltimore Eye Survey. Am J Epidemiol 1991;134:1102-10.
7. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9.
8. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population based study in the Netherlands. The Rott erdam Study. Ophthalmology 1994;101:1851-5.
9. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: The Tajimi Study. Ophthalmology 2004;111:1641-8.
10. Kim JH, Kang SY, Kim NR, Lee ES, Hong S, Seong GJ, et al. Prevalence and characteristics of glaucoma among Korean adults. Korean J Ophthalmol 2011;25:110-15.
11. Shields MB. Normal tension glaucoma: Is it different from primary open-angle glaucoma? Curr Opin Ophthalmol 2008;19:85-8.
12. Caprioli J, Spaeth GL. Comparison of the optic nerve head in high- and low-tension glaucoma. Arch Ophthalmol 1985;103:1145-9.
13. Tezel G, Kass MA, Kolker AE, Wax MB. Comparative optic disc analysis in normal pressure glaucoma, primary open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:2105-13.
14. Ishida K, Yamamoto T, Sugiyama K, Kitazawa Y. Disk hemorrhage is a significantly negative prognostic factor in normal-tension glaucoma. Am J Ophthalmol 2000;129:707-14.
15. Buus DR anderson DR. Peripapillary crescents and halos in normal-tension glaucoma and ocular hypertension. Ophthalmology 1989;96:16-9.
16. Javitt JC, Spaeth GL, Katz LJ, Poryzees E, Addiego R. Acquired pits of the optic nerve: Increased prevalence in patients with low-tension glaucoma. Ophthalmology 1990;97:1038-43.
17. Nduaguba C, Ugurlu S, Caprioli J. Acquired pits of the optic nerve in glaucoma: Prevalence and associated visual field loss. Acta Ophthalmol Scand 1998;76:273-7.
18. Ugurlu S, Weitz man M, Nduaguba C, Caprioli J. Acquired pit of the optic nerve: A risk factor for progression of glaucoma. Am J Ophthalmol 1998;125:457-64.
19. Caprioli J, Spaeth GL. Comparison of visual field defects in the low-tension glaucomas with those in the high-tension glaucomas. Am J Ophthalmol 1984;97:730-7.
20. Chauhan BC, Drance SM, Douglas GR, Johnson CA. Visual field damage in normal-tension and high-tension glaucoma. Am J Ophthalmol 1989;108:636-42.
21. Harrington DO. The pathogenesis of the glaucoma field: Clinical evidence that circulatory insufficiency in the optic nerve is the primary cause of visual field loss in glaucoma. Am J Ophthalmol 1959;47:177-85.
22. Haas JS. Low tension glaucoma. Trans Pac Coast Otoophthalmol Soc Annu Meet 1962;43:153-60.
23. Chung HS, Harris A, Kagemann L, Martin B. Peripapillary retinal blood flow in normal tension glaucoma. Br J Ophthalmol 1999;83:466-9.
24. Anderson DR. Glaucoma, capillaries and pericytes: 1. Blood flow regulation. Ophthalmologica 1996;210:257-62.
25. Johnson DG, Drance SM. Some studies on the circulation in patients with advanced open angle glaucoma. Can J Ophthalmol 1968;3:149-53.
26. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995;113:216-21.
27. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol 2002;120:954-9.
28. Choi J, Jeong J, Cho H, Kook MS. Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: A risk factor for normal tension glaucoma. Invest Ophthalmol Vis Sci 2006;47:831-36.
29. Leske MC. Ocular perfusion pressure and glaucoma: Clinical trial and epidemiological findings. Curr Opin Ophthalmol 2009;20:73-8.
30. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; Early Manifest Glaucoma Trial Group. Predictors of long term progression in the early manifest glaucoma trial. Ophthalmology 2007;11:1965-72.
31. Mroczkowska S, Ekart A, Sung V, Negi A, Qin L, Patel SR, et al. Coexistence of macro- and micro-vascular abnormalities in newly diagnosed normal tension glaucoma patients. Acta Ophthalmol 2012;90:e553-9.
32. Mojon DS, Hess CW, Goldblum D, Fleischhauer J, Koerner F, Bassetti C, et al. High prevalence of glaucoma in patients with sleep apnea syndrome. Ophthalmology 1999;106:1009-12.
33. Mojon DS, Hess CW, Goldblum D, Boehnke M, Koerner F, Gugger M, et al. Normal-tension glaucoma is associated with sleep apnea syndrome. Ophthalmologica 2002;216:180-4.
34. Sergi M, Salerno DE, Rizzi M, Blini Mandreoli A, Messenio D, et al. Prevalence of normal tension glaucoma in obstructive sleep apnea syndrome patients. J Glaucoma 2007;16:42-6.
35. Drance Sanderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699-708.
36. Phelps CD, Corbett JJ. Migraine and low-tension glaucoma. A case-control study. Invest Ophthalmol Vis Sci 1985;26:1105-8.
37. Alvarez-Sala R, Diaz S, Prados C. Increase of intraocular pressure during nasal CPAP. Chest 1992;101:1477.
38. Kiekens S, Groot VD, Coecklbergh T, Tassignon MJ, van de HP, Backer WD, et al. Continuous positive airway pressure therapy is associated with an increase in intraocular pressure in obstructive sleep apnea. Invest Ophthalmol Vis Sci 2008;49:934-40.
39. Kaiser HJ, Flammer J, Wenk M, Luscher T. Endothelin-1 plasma levels in normal-tension glaucoma: Abnormal response to postural changes. Graefes Arch Clin Exp Ophthalmol 1995;233:484-8.
40. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous endothelin levels in primary open-angle glaucoma. J Glaucoma 1997;6:83-9.
41. Iwabe S, Lamas M, Vasquez Pelaez CG, Carrasco FG. Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) in Mexican glaucomatous patients. Curr Eye Res 2010;35:287-94.
42. Sin BH, Song BJ, Park SP. Aqueous vascular endothelial growth factor and endothelin-1 levels in branch retinal vein occlusion associated with normal tension glaucoma. J Glaucoma 2013;22:104-9.
43. Källberg ME, Brooks DE, Garcia-Sanchez GA, Komaromy AM, Szabo NJ, Tian L. Endothelin 1 levels in the aqueous humor of dogs with glaucoma. J Glaucoma 2002;11:105-9.
44. Ghanem AA, Elewa AM, Arafa LF. Endothelin-1 and nitric oxide levels in patients with glaucoma. Ophthalmic Res 2011;46:98-102.
45. Galassi F, Giambene B, Varriale R. Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma. Invest Ophthalmol Vis Sci 2011;52:4467-71.
46. Wollensak G, Schaefer HE, Ihling C. An immunohistochemical study of endothelin-1 in the human eye. Curr Eye Res 1998;17:541-5.
47. Sasaoka M, Taniguchi T, Shimazawa M, Ishida N, Shimazaki A, Hara H. Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits. Exp Eye Res 2006;83:629-37.
48. Lau J, Dang M, Hockmann K, Ball AK. Effects of acute delivery of endothelin-1 on retinal ganglion cell loss in the rat. Exp Eye Res 2006;82:132-45.
49. Taniguchi T, Shimazawa M, Sasaoka M, Shimazaki A, Hara H. Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve. Curr Neurovasc Res 2006;3:81-8.
50. Buckley C, Hadoke PW, Henry E, O'Brien C. Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. Br J Ophthalmol 2002;86:227-32.
51. Cellini M, Strobbe E, Gizzi C, Balducci N, Toschi PG, Campos EC. Endothelin-1 plasma levels and vascular endothelial dysfunction in primary open angle glaucoma. Life Sci 2012;91:699-702.
52. Lee NY, Park HY, Na KS, Park SH, Park CK. Association between heart rate variability and systemic endothelin-1 concentration in normal-tension glaucoma. Curr Eye Res 2012;38:516-9.
53. Tezel G, Wax MB. Increased production of tumor necrosis factor-α by glial cells exposed to stimulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000;20:8693-700.
54. Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 2010;51:903-6.
55. Shohami E, Bass R, Wallach D, Yamin A, Gallily R. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J Cerebr Blood Flow Metab 1996;16:378-84.
56. Cartwright MJ, Grajewski AL, Friedberg ML anderson DR, Richards DW. Immune-related disease and normal-tension glaucoma. A case-control study. Arch Ophthalmol 1992;110:500-2.
57. Wax MB, Barrett DA, Pestronk A. Increased incidence of paraproteinemia and autoantibodies in patients with normalpressure glaucoma. Am J Ophthalmol 1994;117:561-8.
58. Romano C, Barrett DA, Li Z, Pestronk A, Wax MB. Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest Ophthalmol Vis Sci 1995;36:1968-75.
59. Grus FH, Joachim SC, Hoffman EM, Pfeiffer N. Complex autoantibody repertoires in patients with glaucoma. Mol Vis 2004;25:132-7.
60. Joachim SC, Grus FH, Pfeiffer N. Analysis of autoantibody repertoires in sera of patients with glaucoma. Eur J Ophthalmol 2003;13:752-8.
61. Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Grus FH. Antibodies to alpha B-crystalllin, vimentin and heat shock protein 70 in aqueous humor of patients with normal tension glaucoma and IgG antibody patt erns against retinal antigen in aqueous humor. Curr Eye Res 2007;32:501-9.
62. Berdahl JP, Fautsch MP, Stinnett SS, Allingham RR. Intracranial pressure in primary open angle glaucoma, normal tension glaucoma and ocular hypertension: A case-control study. Invest Ophthalmol Vis Sci 2008;49:5412-8.
63. Ren R, Jonas JB, Tian G. Cerebrospinal fluid pressure in glaucoma: A prospective study. Ophthalmology 2010;117:259-66.
64. Morgan WH, Yu DY, Alder VA, Cringle SJ, Cooper RL, House PH, et al. The correlation between the cerebrospinal fluid pressure and retrolaminar tissue pressure. Invest Ophthalmol Vis Sci 1998;39:1419-28.
65. Morgan WH, Yu DY, Cooper RL, Alder VA, Cringle SJ, Constable IJ. The influence of cerebrospinal fluid pressure on the lamina cribrosa tissue pressure gradient. Invest Ophthalmol Vis Sci 1995;36:1163-72.
66. Berdahl JP, Fleischman D, Zadylarova J, Stinnett S, Allingham RR, Fautsch MP. Body mass index has a linear relationship with cerebrospinal fluid pressure. Invest Ophthalmol Vis Sci 2012;53:1422-7.
67. Asrani S, Samuels B, Thakur M, Santiago C, Kuchibhatla M. Clinical profiles of primary open angle glaucoma versus normal tension glaucoma patients: A pilot study. Curr Eye Res 2011;36:429-35.
68. Leske MC, Connell AM, Wu SY, Hyman LG, Schachat AP. Risk factors for open-angle glaucoma. The Barbados Eye Study. Arch Ophthalmol 1995;113:918-24.
69. Pasquale LP, Willett WC, Rosner BA, Kang JE. Anthropometric measures and their relation to incident primary open-angle glaucoma. Ophthalmology 2010;117:1521-9.
70. Ramdas WD, Wolfs RC, Hofman A, de Jong PT, Vingerling JR, Jansonius NM. Lifestyle and risk of developing open-angle glaucoma: The Rotterdam Study. Arch Ophthalmology. 2011;129:767-72.
71. Collaborative Normal-tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
72. The Collaborative Normal-tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal tension glaucoma. Am J Ophthalmol 1998;126:498-505.
73. Drance Sanderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699-708.
74. Drance Sanderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology 2001;108:247-53.
75. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW; Low-Pressure Glaucoma Study Group. The low-pressure glaucoma treatment study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005;112:376-85.
76. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: Results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151:671-81.
77. Gulati V, Fan S, Zhao M, Maslonka MA, Gangahar C, Toris CB. Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy. Arch Ophthalmol 2012;130:677-84.
78. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999;128:301-19.
79. Saylor M, McLoon HK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: An evidence-based review. Arch Ophthalmol 2009;127:402-6.
80. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984;25:776-8.
81. Liu JH, Medeiros FA, Slight JR, Weinreb RH. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 2009;116:449-54.
82. Lee AC, Mosaed S, Weinreb RN, Kripke DF, Liu JH. Effect of laser trabeculoplasty on nocturnal intraocular pressure in medically treated glaucoma patients. Ophthalmology 2007;114:666-70.
83. Nagar M, Luhishi E, Shah N. Intraocular pressure control and fluctuation: The effect of treatment with selective laser trabeculoplasty. Br J Ophthalmol 2009;93:497-501.
84. Heijl A, Leske MC, Hyman L, Yang Z, Bengtsson B; EMGT Group. Intraocular pressure reduction with a fixed treatment protocol in the Early Manifest Glaucoma Trial. Acta Ophtalmol 2011;89:749-54.
85. Zacharia PT, Deppermann SR, Schuman JS. Ocular hypotony after trabeculectomy with mitomycin C. Am J Ophthalmol 1993;116:314-26.
86. Klink T, Praetorius S, Leippi S, Klink J, Grehn FJ. Diurnal and nocturnal intraocular pressure fluctuations after trabeculectomy. Ophthalmologica 2012;227:160-5.
87. Hirooka K, Takenaka H, Baba T, Takagishi M, Mizote M, Shiraga F. Effect of trabeculectomy on intraocular pressure fluctuation with postural change in eyes with open-angle glaucoma. J Glaucoma 2009;18:689-91.
88. nd. Practice preferences for glaucoma surgery: A survey of the American Glaucoma Society in 2008. Ophthalmic Surg Lasers Imaging 2011;42:202-8.
89. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy Study after five years of follow-up. Am J Ophthalmol 153:789-803.
90. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC; Tube versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy Study (TVT) during five years of follow-up. Am J Ophthalmol 2012;153:804-14.
91. Tran DH, Souza C, Ang MJ, Loman J, Law SK, Coleman AL, et al. Comparison of long-term surgical success of Ahmed Valve implant versus trabeculectomy in open-angle glaucoma. Br J Ophthalmol 2009;93:1504-9.
92. Lachkar Y, Neverauskiene J, Jeanteur-Lunel MN, Gracies H, Berkani M, Ecoffet M, et al. Nonpenetrating deep sclerectomy: A 6-year retrospective study. Eur J Ophthalmol 2004;14:26-36.
93. El Sayyad F, Helal M, El-Kholify H, Khalil M, El-Maghraby A. Nonpenetrating deep sclerectomy versus trabeculectomy in bilateral primary open-angle glaucoma. Ophthalmology 2000;107:1671-4.
94. Cillino S, Di Pace F, Casuccio A, Lodato G. Deep sclerectomy versus punch trabeculectomy: Effect of low-dosage mitomycin C. Ophthalmologica 2005;219:281-6.
95. Russo V, Scott IU, Stella A, Balducci F, Cosma A, Barone A, et al. Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculectomy: A prospective clinical trial. Eur J Ophthalmol 2008;18:751-7.
96. Leszczynski R, Forminska-Kapuscik M, Bubula-Stachowicz B, Mrukwa-Kominek E, Filipek E, Pawlicki K. Nonpenetrating very deep sclerectomy with hyaluronic acid implant vs trabeculectomy-A 2-year follow-up. Graefes Arch Clin Exp Ophthalmol 2012;250:1835-41.
97. Martin KR, Levkovitch-Verbin H, Valenta D, Baumrind L, Pease ME, Quigley HA. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest Ophthalmol Vis Sci 2002;43:2236-43.
98. Vorwerk CK, Gorla MS, Dreyer EB. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol 1999;43:S142-50.
99. Guo L, Salt TE, Maass A, Luong V, Moss SE, Fitz ke FW, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006;47:626-33.
100. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-7.
101. Kim TW, Kim DM, Park KH, Kim H. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 2002;16:1-7.
102. Schuettauf F, Quinto K, Naskar R, Zurakowski D. Effects of antiglaucoma medications on ganglion cell survival: The DBA/2J mouse model. Vis Res 2002;42:2333-7.
103. Hare WA, WoldeMussie E, Weinreb RN, Ton H, Ruiz G, Wijono M, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest Ophthalmol Vis Sci 2004;45:2640-51.
104. Hare WA, WoldeMussie E, Lai RK, Ton H, Ruiz G, Chun T, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci 2004;45:2625-39.
105. Yucel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, Weinreb RW. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006;124:217-25.
106. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009;87:450-4.
107. Harms NV, Toris CB. Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease. Expert Opin Pharmacother 2013;14:105-13.
108. Polska E, Doelemeyer A, Luksch A, Ehrlich P, Kaehler N, Percicot CL, et al. Partial antagonism of endothelin 1-induced vasoconstriction in the human choroid by topical unoprostone isopropyl. Arch Ophthalmol 2002;120:348-52.
109. Munemasa Y, Kitaoka Y, Hayashi Y, Takeda H, Fujino H, Ohtani-Kaneko R, et al. Effects of unoprostone on phosphorylated extracellular signal-regulated kinase expression in endothelin 1-induced retinal and optic nerve damage. Vis Neurosci 2008;25:197-208.
110. Araie M, Mayama C. Use of calcium channel blockers for glaucoma. Prog Retin Eye Res 2011;30:54-71.
111. Gasser P, Flammer J. Influence of vasospasm on visual function. Doc Ophthalmol 1987;66:3-18.
112. Gasser P, Flammer J. Short- and long-term effect of nifedipine on the visual field in patients with presumed vasospasm. J Int Med Res 1990;18:334-9.
113. Gasser P, Flammer J, Guthauser U, Mahler F. Do vasospasms provoke ocular diseases? Angiology 1990;41:213-20.
114. Bose S, Piltz JR, Breton ME. Nimodipine, a centrally active calcium antagonist, exerts a beneficial effect on contrast sensitivity in patients with normal-tension glaucoma and in control subjects. Ophthalmology 1995;102:1236-41.
115. Luksch A, Rainer G, Koyuncu D, Ehrlich P, Maca T, Gschwandtner ME, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. Br J Ophthalmol 2005;89:221-5.
116. Michalk F, Michelson G, Harazny J, Werner U, Daniel WG, Werner D. Single-dose nimodipine normalizes impaired retinal circulation in normal tension glaucoma. J Glaucoma 2004;13:158-62.
117. Strenn K, Matulla B, Wolzt M, Findl O, Bekes MC, Lamsfuss U, et al. Reversal of endothelin-1 induced ocular hemodynamic effects by low-dose nifedipine in humans. Clin Pharmacol Ther 1998;63:54-63.
118. Piltz JR, Bose S, Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and macular blood flow in patients with normal-tension glaucoma and in control subjects. J Glaucoma 1998;7:336-42.
119. Gaspar AZ, Flammer J, Hendrickson P. Influence of nifedipine on the visual fields of patients with optic-nerve-head diseases. Eur J Ophthalmol 1994;4:24-8.
120. Harris A, Evans DW, Cantor LB, Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am J Ophthalmol 1997;124:296-302.
121. Rainer G, Kiss B, Dallinger S, Findl O, Georgopolous M, Vass C, et al. A double masked placebo controlled study on the effect of nifedipine on optic nerve blood flow and visual field function in patients with open angle glaucoma. Br J Clin Pharmacol 2001;52:210-2.
122. Santafe J, De Ibarreta MJ, Segarra J, Melena J. A long-lasting hypotensive effect of topical diltiazem on the intraocular pressure in conscious rabbits. Naunyn-Schmiedebergs Arch Pharmacol 1997;355:645-50.
123. Santafe J, De Ibarreta MJ, Segarra J, Melena J. The effect of topical diltiazem on hypertension induced by water loading in rabbits. Gen Pharmacol 1999;32:201-5.
124. Melena J, Santafe J, Segarra J. The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits. J Pharmacol Exp Ther 1998;284:278-82.
125. Siegner SW, Netland PA, Schroeder A, Erickson KA. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J Glaucoma 2000;9:334-9.
126. Segarra J, Santafe J, De Ibarreta MJ. The topical application of verapamil and nifedipine lowers intraocular pressure in conscious rabbits. Gen Pharmacol 1993;24:1163-71.
127. Netland PA, Feke GT, Konno S, Goger DG, Fujio N. Optic nerve head circulation after topical calcium channel blocker. J Glaucoma 1996;5:200-6.
128. Netland PA, Grosskreutz CL, Feke GT, Hart LJ. Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am J Ophthalmol 1995;119:694-700.
129. Abreu MM, Kim YY, Shin DH, Netland PA. Topical verapamil and episcleral venous pressure. Ophthalmology 1998;105:2251-5.
130. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: General mechanisms and putative role of stress proteins. Restor Neurol Neurosci 2006;24:79-95.
131. Bosel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurons. J Neurochem 2005;92:1386-98.
132. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 2007;282:26832-44.
133. Owen CG, Carey IM, Shah S, de Wilde S, Wormald R, Whincup PH, et al. Hypotensive medications, statins and the risk of glaucoma. Invest Ophthalmol Vis Sci 2010;51:3524-30.
134. Stein JD Newman-Casey PA, Talwar N, Nan B, Richards JE, Musch DC. The relationship between statin use and open-angle glaucoma. Ophthalmology 2012;119:2074-81.
135. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: An adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis 2012;18:390-402.
136. Ou HC, Lee WJ, Lee IT, Chiu TH, Tsai KL, Lin CY, et al. Ginkgo biloba extract att enuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol 2009;106:1674-85.
137. Eckert A, Keil U, Scherping I, Hauptmann S, Muller WE. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by ginkgo biloba extract EGb 761. Ann NY Acad Sci 2005;1056:474-85.
138. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of gingko biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol 2011;25:323-8.
139. Chung SY, Cheng FC, Lee MS, Lin JY, Lin MC, Wang MF. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. Am J Chin Med 2006;34:803-17.
140. Shah ZA, Nada SE, Dore S. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection. Neuroscience 2011;180:248-55.
141. Quaranta L, Bett elli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 2003;110:359-62.
142. Lee J, Sohn SW, Kee C. Effect of gingko biloba extract on visual field progression in normal tension glaucoma. J Glaucoma 2012;22:780-4.
143. Shim SH, Kim JM, Choi CY, Kim CY, Park KH. Gingko biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food 2012;15:818-23.
144. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
145. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Ragione FD. Resveratrol: From Basic Science to the Clinic. Cell Cycle 2007;6:2495-510.
146. Mozaffarieh M, Grieshaber MC, Orgul S, Flammer J. The potential value of natural antioxidative treatment in glaucoma. Surv Ophthalmol 2008;53:479-505.
147. Luna C, Li G, Liton PB, Qiu J, Epstein DL, Challa P, et al. Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells. Food Chem Toxicol 2009;47:198-204.